Toshinori Hirai

Dr. Toshinori Hirai

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2021 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
THToshinori Hirai
Toshinori Hirai
KHKeiko Hosohata
Keiko Hosohata
YOYukari Ogawa
Yukari Ogawa
TITakuya Iwamoto
Takuya Iwamoto

15 February 2019 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
THToshinori Hirai
Toshinori Hirai
KHKazuhiko Hanada
Kazuhiko Hanada
AKAyako Kanno
Ayako Kanno
MAMegumi Akashi
Megumi Akashi
TIToshimasa Itoh
Toshimasa Itoh

23 May 2019 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
THToshinori Hirai
Toshinori Hirai
YSYukari Shuji
Yukari Shuji
MTMegumi Takiyama
Megumi Takiyama
KHKazuhiko Hanada
Kazuhiko Hanada
TIToshimasa Itoh
Toshimasa Itoh

24 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
THToshinori Hirai
Toshinori Hirai
MNMasanori Nashi
Masanori Nashi
Candida spp. are common components of normal microbiota in the oral cavity. However, Candida albicans can be a primary cause of superficial infections in the oral cavity and esophagus, especially in immunocompromised individuals. While these infections are rarely life-threatening, they can significantly impair quality of life and, in severe cases, progress to hematogenous dissemination. Oral candidiasis often exhibits as pseudomembranous, erythematous (atrophic), chronic hyperplastic, denture stomatitis, or angular cheilitis. Esophageal candidiasis is typically diagnosed by upper endoscopy, which involves histological examination and brushing. Clinical guidelines recommend topical antifungal agents for mild oral candidiasis, and systemic agents for moderate-to-severe disease or when topical therapy fails. However, azole antifungals pose a substantial risk of drug–drug interactions, primarily due to the inhibition of cytochrome P450 enzymes and drug transporters, which dramatically alters the pharmacokinetics of co-administered drugs. Additionally, amphotericin B, a polyene macrolide antibiotic, may cause nephrotoxicity and electrolyte disturbances (e.g., hypokalemia and hypomagnesemia). Moreover, the co-administration of nephrotoxic drugs may augment the toxicity associated with amphotericin B. Therefore, this review aimed to provide a comprehensive overview of the management of oral and esophageal candidiasis from the viewpoint of clinical pharmacology, with a particular focus on drug–drug interactions and adverse effect profiles.

1 November 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
THToshinori Hirai
Toshinori Hirai
RYRyosuke Yamaga
Ryosuke Yamaga
YIYutori Ishikawa
Yutori Ishikawa
KHKazuhiko Hanada
Kazuhiko Hanada
TITakuya Iwamoto
Takuya Iwamoto
TIToshimasa Itoh
Toshimasa Itoh

10 February 2022 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
THToshinori Hirai
Toshinori Hirai
HKHidefumi Kasai
Hidefumi Kasai
MNMiyoko Naganuma
Miyoko Naganuma
NHNobuhisa Hagiwara
Nobuhisa Hagiwara
TSTsuyoshi Shiga
Tsuyoshi Shiga
Background: Digoxin is an important treatment option for reducing the ventricular rate in patients with atrial fibrillation (AF) and heart failure (HF). Digoxin has a narrow therapeutic window and large interindividual variability. A low target blood concentration, especially ≤0.9 ng/mL, is recommended for patients with HF who are taking digoxin. This study aimed to develop a population pharmacokinetic model and to identify clinical factors that affect digoxin exposure and an optimal digoxin dosing regimen in Japanese patients with AF and HF. Methods: A population pharmacokinetic analysis was performed by using a nonlinear mixed effects model based on 3465 concentration points from 391 patients (>18 years) who were receiving oral digoxin. Using trough serum digoxin concentrations and clinical data, a population pharmacokinetic model was developed for determining covariates of clearance. A 1-compartment model was used to examine the interindividual variability of the oral clearance (CL/F) of digoxin. An appropriate dosage of digoxin was identified using Monte Carlo simulation. Results: The final model demonstrated that creatinine clearance (CLCR) and the use of amiodarone were factors that contributed to the CL/F of digoxin. Monte Carlo simulation results showed that with a daily maintenance dose of 0.25 mg, the intoxication risk window of a trough serum concentration of ≥0.9 ng/mL could be reached in more than half of patients regardless of renal function category or concurrent use of amiodarone. The appropriate maintenance dosage was 0.125 mg daily for most Japanese patients with AF and HF. However, with a daily dose of 0.125 mg, a trough serum concentration of ≥0.9 ng/mL could be reached in more than half of patients with renal impairments (CLCR 30 mL/min) or concurrent use of amiodarone. A daily maintenance dose of 0.0625 mg was acceptable for these patients. Conclusions: CLCR and the use of amiodaron were found to contribute to digoxin clearance using a population pharmacokinetic methodology. For Japanese patients with AF and HF, 0.125 mg is an appropriate daily digoxin maintenance dose, but a dose reduction is required for patients with CLCR <30 mL/min or concurrent amiodarone use.